Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective increased by Jefferies Financial Group from $54.00 to $58.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 24.81% from the stock’s current price.

Several other research firms also recently commented on TARS. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Trading Up 6.7 %

Shares of NASDAQ TARS opened at $46.47 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business’s 50 day moving average price is $50.14 and its 200-day moving average price is $43.61. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -12.20 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in TARS. Toronto Dominion Bank acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth $105,714,000. Jennison Associates LLC raised its stake in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after acquiring an additional 685,111 shares during the last quarter. Millennium Management LLC raised its stake in Tarsus Pharmaceuticals by 189.4% in the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock worth $35,659,000 after acquiring an additional 421,495 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after acquiring an additional 420,057 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.